Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells

Anne Laure Flamar, Yaming Xue, Sandra M. Zurawski, Monica Montes, Bryan King, Louis Sloan, SangKon Oh, Jacques Banchereau, Yves Levy, Gerard Zurawski

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective: Targeting HIV antigens directly to dendritic cells using monoclonal antibodies against cell-surface receptors has been shown to evoke potent cellular immunity in animal models. The objective of this study was to configure an anti-human CD40 antibody fused to a string of five highly conserved CD4+ and CD8+ T-cell epitope-rich regions of HIV-1 Gag, Nef and Pol (αCD40.HIV5pep), and then to demonstrate the capacity of this candidate therapeutic vaccine to target these HIV peptide antigens to human dendritic cells to expand functional HIV-specific T cells. Methods: Antigen-specific cytokine production using intracellular flow cytometry and multiplex bead-based assay, and suppression of viral inhibition, were used to characterize the T cells expanded by αCD40.HIV5pep from HIV-infected patient peripheral blood mononuclear cell (PBMC) and dendritic cell/T-cell co-cultures. Results: This candidate vaccine expands memory CD4+ and CD8+ T cells specific to multiple epitopes within all five peptide regions across a wide range of major histocompatibility complex (MHC) haplotypes from HIV-infected patient PBMC and dendritic cell/T-cell co-cultures. These in vitro expanded HIV antigen-specific CD4+ and CD8+ T cells produce multiple cytokines and chemokines. αCD40.HIV5pepexpanded CD8 + T cells have characteristics of cytotoxic effector cells and are able to kill autologous target cells and suppress HIV-1 replication in vitro. Conclusion: Our data demonstrate the therapeutic potential of this CD40-targeting HIV candidate vaccine in inducing a broad repertoire of multifunctional T cells in patients.

Original languageEnglish (US)
Pages (from-to)2041-2051
Number of pages11
JournalAIDS
Volume27
Issue number13
DOIs
StatePublished - Aug 24 2013
Externally publishedYes

Fingerprint

HIV Antigens
T-Lymphocytes
Dendritic Cells
HIV
Coculture Techniques
HIV-1
Blood Cells
Vaccines
Cell Culture Techniques
Cytokines
AIDS Vaccines
Peptides
T-Lymphocyte Epitopes
Cell Surface Receptors
Major Histocompatibility Complex
Chemokines
Cellular Immunity
Haplotypes
Epitopes
Flow Cytometry

Keywords

  • CD40
  • Dendritic cell
  • HIV
  • T cell
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Flamar, A. L., Xue, Y., Zurawski, S. M., Montes, M., King, B., Sloan, L., ... Zurawski, G. (2013). Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells. AIDS, 27(13), 2041-2051. https://doi.org/10.1097/QAD.0b013e3283624305

Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells. / Flamar, Anne Laure; Xue, Yaming; Zurawski, Sandra M.; Montes, Monica; King, Bryan; Sloan, Louis; Oh, SangKon; Banchereau, Jacques; Levy, Yves; Zurawski, Gerard.

In: AIDS, Vol. 27, No. 13, 24.08.2013, p. 2041-2051.

Research output: Contribution to journalArticle

Flamar, AL, Xue, Y, Zurawski, SM, Montes, M, King, B, Sloan, L, Oh, S, Banchereau, J, Levy, Y & Zurawski, G 2013, 'Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells', AIDS, vol. 27, no. 13, pp. 2041-2051. https://doi.org/10.1097/QAD.0b013e3283624305
Flamar, Anne Laure ; Xue, Yaming ; Zurawski, Sandra M. ; Montes, Monica ; King, Bryan ; Sloan, Louis ; Oh, SangKon ; Banchereau, Jacques ; Levy, Yves ; Zurawski, Gerard. / Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells. In: AIDS. 2013 ; Vol. 27, No. 13. pp. 2041-2051.
@article{3099424ed43b49ba915ae30abc9da314,
title = "Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells",
abstract = "Objective: Targeting HIV antigens directly to dendritic cells using monoclonal antibodies against cell-surface receptors has been shown to evoke potent cellular immunity in animal models. The objective of this study was to configure an anti-human CD40 antibody fused to a string of five highly conserved CD4+ and CD8+ T-cell epitope-rich regions of HIV-1 Gag, Nef and Pol (αCD40.HIV5pep), and then to demonstrate the capacity of this candidate therapeutic vaccine to target these HIV peptide antigens to human dendritic cells to expand functional HIV-specific T cells. Methods: Antigen-specific cytokine production using intracellular flow cytometry and multiplex bead-based assay, and suppression of viral inhibition, were used to characterize the T cells expanded by αCD40.HIV5pep from HIV-infected patient peripheral blood mononuclear cell (PBMC) and dendritic cell/T-cell co-cultures. Results: This candidate vaccine expands memory CD4+ and CD8+ T cells specific to multiple epitopes within all five peptide regions across a wide range of major histocompatibility complex (MHC) haplotypes from HIV-infected patient PBMC and dendritic cell/T-cell co-cultures. These in vitro expanded HIV antigen-specific CD4+ and CD8+ T cells produce multiple cytokines and chemokines. αCD40.HIV5pepexpanded CD8 + T cells have characteristics of cytotoxic effector cells and are able to kill autologous target cells and suppress HIV-1 replication in vitro. Conclusion: Our data demonstrate the therapeutic potential of this CD40-targeting HIV candidate vaccine in inducing a broad repertoire of multifunctional T cells in patients.",
keywords = "CD40, Dendritic cell, HIV, T cell, Vaccine",
author = "Flamar, {Anne Laure} and Yaming Xue and Zurawski, {Sandra M.} and Monica Montes and Bryan King and Louis Sloan and SangKon Oh and Jacques Banchereau and Yves Levy and Gerard Zurawski",
year = "2013",
month = "8",
day = "24",
doi = "10.1097/QAD.0b013e3283624305",
language = "English (US)",
volume = "27",
pages = "2041--2051",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "13",

}

TY - JOUR

T1 - Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells

AU - Flamar, Anne Laure

AU - Xue, Yaming

AU - Zurawski, Sandra M.

AU - Montes, Monica

AU - King, Bryan

AU - Sloan, Louis

AU - Oh, SangKon

AU - Banchereau, Jacques

AU - Levy, Yves

AU - Zurawski, Gerard

PY - 2013/8/24

Y1 - 2013/8/24

N2 - Objective: Targeting HIV antigens directly to dendritic cells using monoclonal antibodies against cell-surface receptors has been shown to evoke potent cellular immunity in animal models. The objective of this study was to configure an anti-human CD40 antibody fused to a string of five highly conserved CD4+ and CD8+ T-cell epitope-rich regions of HIV-1 Gag, Nef and Pol (αCD40.HIV5pep), and then to demonstrate the capacity of this candidate therapeutic vaccine to target these HIV peptide antigens to human dendritic cells to expand functional HIV-specific T cells. Methods: Antigen-specific cytokine production using intracellular flow cytometry and multiplex bead-based assay, and suppression of viral inhibition, were used to characterize the T cells expanded by αCD40.HIV5pep from HIV-infected patient peripheral blood mononuclear cell (PBMC) and dendritic cell/T-cell co-cultures. Results: This candidate vaccine expands memory CD4+ and CD8+ T cells specific to multiple epitopes within all five peptide regions across a wide range of major histocompatibility complex (MHC) haplotypes from HIV-infected patient PBMC and dendritic cell/T-cell co-cultures. These in vitro expanded HIV antigen-specific CD4+ and CD8+ T cells produce multiple cytokines and chemokines. αCD40.HIV5pepexpanded CD8 + T cells have characteristics of cytotoxic effector cells and are able to kill autologous target cells and suppress HIV-1 replication in vitro. Conclusion: Our data demonstrate the therapeutic potential of this CD40-targeting HIV candidate vaccine in inducing a broad repertoire of multifunctional T cells in patients.

AB - Objective: Targeting HIV antigens directly to dendritic cells using monoclonal antibodies against cell-surface receptors has been shown to evoke potent cellular immunity in animal models. The objective of this study was to configure an anti-human CD40 antibody fused to a string of five highly conserved CD4+ and CD8+ T-cell epitope-rich regions of HIV-1 Gag, Nef and Pol (αCD40.HIV5pep), and then to demonstrate the capacity of this candidate therapeutic vaccine to target these HIV peptide antigens to human dendritic cells to expand functional HIV-specific T cells. Methods: Antigen-specific cytokine production using intracellular flow cytometry and multiplex bead-based assay, and suppression of viral inhibition, were used to characterize the T cells expanded by αCD40.HIV5pep from HIV-infected patient peripheral blood mononuclear cell (PBMC) and dendritic cell/T-cell co-cultures. Results: This candidate vaccine expands memory CD4+ and CD8+ T cells specific to multiple epitopes within all five peptide regions across a wide range of major histocompatibility complex (MHC) haplotypes from HIV-infected patient PBMC and dendritic cell/T-cell co-cultures. These in vitro expanded HIV antigen-specific CD4+ and CD8+ T cells produce multiple cytokines and chemokines. αCD40.HIV5pepexpanded CD8 + T cells have characteristics of cytotoxic effector cells and are able to kill autologous target cells and suppress HIV-1 replication in vitro. Conclusion: Our data demonstrate the therapeutic potential of this CD40-targeting HIV candidate vaccine in inducing a broad repertoire of multifunctional T cells in patients.

KW - CD40

KW - Dendritic cell

KW - HIV

KW - T cell

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84884499897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884499897&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e3283624305

DO - 10.1097/QAD.0b013e3283624305

M3 - Article

C2 - 23615121

AN - SCOPUS:84884499897

VL - 27

SP - 2041

EP - 2051

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 13

ER -